Bivalirudin during Primary PCI in Acute Myocardial Infarction

Abstract

In patients with ST-segment elevation myocardial infarction who are undergoing primary PCI, anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in significantly reduced 30-day rates of major bleeding and net adverse clinical events. (ClinicalTrials.gov number, NCT00433966 [ClinicalTrials.gov].).

Keywords

Affiliated Institutions

• Columbia University Irving Medical Center US
• New York Hospital Queens US
• NewYork–Presbyterian Hospital US
• Rabin Medical Center IL
• London School of Hygiene & Tropical Medicine GB
• Franklin University US
• Silesian Center for Heart Disease PL
• Jagiellonian University PL
• University Hospital Schleswig-Holstein DE
• Cardiovascular Research Foundation US
• University of Lübeck DE
• Charité - Universitätsmedizin Berlin DE
• Moses H Cone Memorial Hospital US
• Presbyterian Hospital US
• Cornell University US
• University of Bergamo IT
• Mayo Clinic in Arizona US

Related Publications